Drugs / EA1080
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04223960 | Jan 2020 → Aug 2023 | — | EA Pharma Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-14 | EA Pharma Co., Ltd. | 欧州クローン病・大腸炎会議（ECCO）2025において開発中の炎症性腸疾患治療薬である経口α4β7阻害剤NSHO-101（EA1080）の 臨床第Ⅰ相試験、1日1回投与データを発表予定 eapharma.co.jp ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EA1080 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04223960 ↗ |
| Route | Oral | “Healthy Caucasian participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1 of SAD part of the study.” NCT04223960 ↗ |